GLOW (GLP-1 Plus Lifestyle for Overall Wellness)
University of Minnesota
Summary
The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.
Description
The premise underpinning our proposed project stems from the conceptual framework that obesity medications beneficially alter the underlying pathophysiology that largely drives eating behaviors (appetite, satiety, cravings, and "food noise"), thereby lessening the need for high doses of HBLT. In this way, medications can unburden adolescents living with obesity, their caregivers, healthcare providers, health systems, and payors from the need to engage in and provide intensive HBLT. This framework has directly informed our research strategy and methodological approach, including the design of o…
Eligibility
- Age range
- 12–18 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Aged 12 to \< 18 years at screening * BMI \>/= 95th percentile based on age and sex at screening * Provide release of information for established primary health provider * Own a device capable of connecting to the virtual platform sessions with video Exclusion Criteria: * Diabetes (type 1 or 2) due to safety concerns about proper surveillance of glycemic control virtually * HbA1c \>/= 6.5% * Current or recent (\< 6 months prior to screening) use of FDA-approved obesity medications * Previous metabolic/bariatric surgery or metabolic/bariatric surgery planned during the…
Interventions
- DrugSemaglutide
All participants in this study will receive treatment with Semaglutide
Location
- University of Minnesota, Center for Pediatric Obesity MedicineMinneapolis, Minnesota